CARRIE WEAVER: Open Payments
NPI 1851065825 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$785 in 37 payments from 13 companies in 2025. Trend: 2023 $111 · 2024 $100 · 2025 $785
Food & beverage: $785
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $114 |
| Supernus Pharmaceuticals, Inc. | 3 | $78 |
| Alkermes, Inc. | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Collegium Pharmaceutical, Inc. | 3 | $64 |
| Lundbeck LLC | 3 | $62 |
| Noven Therapeutics, LLC | 3 | $61 |
| ABBVIE INC. | 2 | $39 |
Products named: REXULTI, Qelbree, ARISTADA, HETLIOZ, TRINTELLIX, Auvelity, Jornay PM, Xelstrym.
Industry payments across NE — which companies pay providers there.
